VISTAGEN THERAPEUTICS, INC. Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount of $0 for the 12-month period ending 2022-03-31, per its 10-K filed 2022-06-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockConvertibleDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount · last filed 2022-06-23
- VISTAGEN THERAPEUTICS, INC. preferred stock convertible down round feature decrease in net income loss to common shareholder amount for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- VISTAGEN THERAPEUTICS, INC. preferred stock convertible down round feature decrease in net income loss to common shareholder amount for fiscal 2021 was $23.00M.
| Period end | Preferred Stock Convertible Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 12 month |
|---|---|
| 2022-03-31 | $0.00 10-K · filed 2022-06-23 |
| 2021-03-31 | $23.00M 10-K · filed 2022-06-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |